They are injected back into the tumor, where they become little bioreactors that release IL-12.

FORBES: End Of An Era: The Last Herper-Langreth Biotech Story

It will move the IL-12 drug and other cancer gene therapy approaches through human trials while Intrexon continues to work on basic science.

FORBES: The Next Big Move For The Smartest Biotech Investor

Arrive at Slow Food-endorsed Il Carroccio (closed Wednesdays) much later than 12:30pm and risk a prolonged wait out on the sidewalk.

BBC: Two days in Siena, Italy